drugset / Trial / NCT03235167

Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy

NCT03235167 ↗

Phase 1 Unknown 100 enrolled Dalian University
RandomizedFactorialQuadruple-blindTreatment

Summary

to observe the outcome of hepatocellular carcinoma patients under the combination treatment of transcatheter arterial chemoembolization (TACE) and CpG DNA

Timeline

Start
2017-10
Primary completion
2022-10
Completion
2022-10

Drugs

EvaluationDrugModalityDoseRoute
Subject CpG DNA Unknown — —